Drug intelligence / Profile preview

GP0116

Development stage: Preclinical
Lead developer: Galderma
Modality: Implantable Devices → Device-based Delivery → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
Administration: Injection

Overview

GP0116 is an injectable, sterile, transparent dermal filler designed for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds. Its mechanism of action is physical volumization and contouring of facial soft tissue, likely through replacement and support using a hyaluronic acid-based gel matrix. GP0116 is being developed by Galderma R&D and is intended for aesthetic treatment in adults with moderate to severe facial wrinkles[3]. Specific pharmacological targets are not provided; its action is based on filling and supporting tissue, not receptor-mediated pharmacology.

Brand names: GP0116GP-0116GP 0116
Other names: GP0116GP-0116GP 0116

Beyond the preview

Go deeper on GP0116.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GP0116.

Explore the full profile